Synchron tests brain chips with 6 humans patients with paralysis
- July 28, 2021 "A small company developing an implantable brain computer interface to help treat conditions like paralysis has received the go-ahead from the Food and Drug Administration (FDA) to kick off clinical trials of its flagship device later this year."
- "The study will start later this year at Mount Sinai Hospital with six human subjects."
- "Synchron has received FDA approval to kick off an early feasibility study of its brain computer interface implant in humans in the U.S. "
- "Synchron is hoping the device will allow patients to use brain data to "control digital devices and achieve improvements in functional independence.""
- Synchron, Inc. is a neurovascular bioelectronics medicine company developing bloodstream-enabled solutions for previously-untreatable nervous system conditions. The company is pioneering the field of interventional neuromodulation and developing the world's first motor neuroprosthesis, the Stentrode Source Click Here
- Synchron, the startup behind an FDA breakthrough neuroprosthesis device that aims to give patients with paralysis the ability to control digital devices with their thoughts, has been cleared by the FDA to begin a clinical trial with human participants.
- The Stentrode device is implanted into the motor cortex of the brain through the jugular vein in a minimally invasive procedure that the company says takes about two hours. Once implanted, it translates brain activity into a standardized digital language to allow users to complete tasks on external devices, including texting, emailing, online shopping and accessing telemedicine.
Stentrode brain chip is implanted within a blood vessel of a patient's brain, along with a power supply and transmitter inserted under the skin in front of the shoulder:
